Vanda Pharmaceuticals (VNDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -13,988 | -8,664 | -4,146 | 2,509 | 4,909 |
| Depreciation Amortization | 680 | 690 | 758 | -4,465 | -5,201 |
| Income taxes - deferred | -4,568 | -1,480 | -246 | -1,286 | 6,198 |
| Accounts receivable | -8,581 | -7,751 | -2,587 | -707 | 4,129 |
| Accounts payable and accrued liabilities | 3,835 | 4,304 | 1,165 | -10,984 | -14,315 |
| Other Working Capital | -7,276 | 2,365 | 6,978 | -747 | -3,567 |
| Other Operating Activity | 15,958 | 11,177 | 5,647 | 28,481 | 24,380 |
| Operating Cash Flow | $-13,940 | $641 | $7,569 | $12,801 | $16,533 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -4,505 | -4,344 | -2,712 | -101,048 | -130 |
| Purchase Of Investment | -272,369 | -188,636 | -76,006 | -512,606 | -457,628 |
| Sale Of Investment | 255,451 | 159,500 | 60,500 | 601,598 | 489,485 |
| Investing Cash Flow | $-21,423 | $-33,480 | $-18,218 | $-12,056 | $31,727 |
| Cash Flows From Financing Activities | |||||
| Financing Cash Flow | $0 | $N/A | $N/A | $N/A | $N/A |
| Exchange Rate Effect | 39 | -29 | -14 | 47 | -103 |
| Beginning Cash Position | 136,290 | 136,290 | 136,290 | 135,498 | 135,498 |
| End Cash Position | 100,966 | 103,422 | 125,627 | 136,290 | 183,655 |
| Net Cash Flow | $-35,324 | $-32,868 | $-10,663 | $792 | $48,157 |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,940 | 641 | 7,569 | 12,801 | 16,533 |
| Capital Expenditure | -4,505 | -4,344 | -2,712 | -101,048 | -130 |
| Free Cash Flow | -18,445 | -3,703 | 4,857 | -88,247 | 16,403 |